Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 355

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 355
---
 plan adjustments                                                             |     |                                        |          — |                  |     |   |     40,850 |             |     |   |         — |       |     |           |     |   |     40,850 |   |
| Effect of exchange rate changes                                                              |     |                                        |     61,000 |                  |     |   |    121,428 |             |     |   |         — |       |     |           |     |   |    182,428 |   |
| Total comprehensive profit                                                                   |     |                                        |     61,000 |                  |     |   |    162,278 |             |     |   |         — |       |     |           |     |   |    223,278 |   |
| Total comprehensive loss                                                                     |     | $                                      | (1,175,329 | )                |     | $ | (1,873,556 | )           |     | $ | 1,198,604 |       |     |           |     | $ | (1,850,281 | ) |
| Basic and diluted loss per share (in USD)                                                    |     | $                                      |      (0.03 | )                |     | $ |      (1.94 | )           |     |   |         — |       |     |           |     | $ |      (0.06 | ) |
| Weighted average common shares used in computing basic and diluted net loss per common share |     |                                        |  4,193,689 |                  |     |   |  1,048,632 |             |     |   |           |       |     |           |     |   | 35,910,102 |   |

The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

195

Kadimastem Ltd. & NLS Pharmaceutics Ltd. Unaudited Pro Forma Condensed Combined Statement of Operations and Other Comprehensive Loss

|                                                                                              |     | For the Twelve Months Ended December 31, 2023 |            |    |     |                  |             |   |     |             |          |   |     |       |     |           |             |   |
|:---------------------------------------------------------------------------------------------|:----|:----------------------------------------------|-----------:|:---|:----|:-----------------|------------:|:--|:----|:------------|---------:|:--|:----